The Lancet. Respiratory medicine
Precision medicine for cell therapy in acute respiratory distress syndrome - Authors' reply.
ECMO in severe acute respiratory distress syndrome.
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.
Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial.
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.
Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study.
Respiratory risks from household air pollution in low and middle income countries.
In control of ambient and household air pollution - how low should we go?
Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?
